Collaborative Cardiovascular Drug Safety and Biomarker Research Program

The summary for the Collaborative Cardiovascular Drug Safety and Biomarker Research Program grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Food and Drug Administration, which is the U.S. government agency offering this grant.

Collaborative Cardiovascular Drug Safety and Biomarker Research Program: Collaborative Cardiovascular Drug Safety and Biomarker Research Program---As Proposed by Congress and to be conducted under FDAs Critical Path Initiative: This collaborative research program is expected to be conducted in a multi-phased process, leveraging resources and expertise from the awardee, other collaborators, and FDA to address public health needs involving cardiovascular disease and biomarker research; Availability of Sole Source Cooperative Agreement; Request for Application: RFA-FDA-OC-2006-1; Catalog of Federal Domestic Assistance Number 93.103. The Food and Drug Administration (FDA), Office of the Commissioner (OC) is announcing its intent to accept and consider a single source application for the award of a Cooperative Agreement to the Critical Path Institute. FDA anticipates providing up to $750,000 (direct and indirect costs combined) in fiscal year 2006 to support this multi-phased research program that will include, but will not be limited to, the development of an infrastructure to support this program and subsequent related studies in cardiovascular disease and genomic/proteomic biomarker research, as stipulated by Congress. Subject to the availability of Federal funds and successful performance, an additional two years of support up to $750,000(direct and indirect costs combined) per year may be available.FDA will support the research covered by this notice under the authority of Section 301 of the Public Health Service (PHS) Act (42 U.S.C. 241). FDAs research program is described in the Catalog of Federal Domestic Assistance No. 93.103. Before entering into cooperative agreements, FDA carefully considers the benefits such agreements will provide to the public.The cooperative agreement ensures FDAs continued participation in the Collaborative Cardiovascular Drug Safety and Biomarker Research Program---As proposed by Congress and to be conducted under FDAs Critical Path Initiative: A goal of the Critical Path Initiative is to foster the development of new tools to both promote drug safety and accelerate the development of innovative new therapies, through appropriate collaboration with multiple parties. For further information or a copy of the complete Request for Applications (RFA) contact Cynthia Polit, Grants Management Officer, Division of Contracts and Grants Management (HFA500), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-7180, e-mail: [email protected] . This RFA can be viewed on Grants.gov under "Grant Find." A copy of the complete RFA can also be viewed on the FDA website at http://www.fda.gov/oc/initiatives/criticalpath/. For issues regarding the programmatic and scientific aspects of this notice: Wendy Sanhai, Ph.D., Senior Scientific Advisor, Office of the Commissioner, FDA, 5600 Fishers Lane, Room 1471 (HF-1) Rockville, MD 20857, 301-827-7867, email: [email protected].